CareDx, Inc. (CDNA) stock

CDNANasdaqServices-Medical LaboratoriesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 12/3023% above fair value

$79.81−1.36 (-1.68%)

Close on Nov 12, 2026Market cap $4.19BP/E 33.4Yield –

CareDx EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

CareDx's EV/EBITDA was 31.1× on Nov 11, 2026, against 11.1× a year earlier. Over the last 2 years it ranged from 7.0× to 280.0×, with a median of 22.9×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	31.1×	+20.6
2025	Dec 31, 2025	10.4×	−71.7
2015	Jul 31, 2015	82.1×	+49.4
2014	Dec 31, 2014	32.7×	–

Where these numbers come from

Parsed from the XBRL in CareDx's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CDNA.

Compare: CDNA vs VCYT · CDNA vs BLLN · CDNA vs BNR · CDNA vs CSTL · CDNA vs FLGT

Revenue growth38.9% · median 13.6%

Operating margin23.4% · median 1.4%

Net margin25.9% · median 2.6%

Company	Revenue	Growth
VCYT	$581.78M	+17.5%
CDNA	$497.40M	+38.9%
BLLN	$436.87M	+71.9%
CSTL	$377.13M	+9.8%
FLGT	$330.28M	+4.7%
BNR	–	–

Company

Next earnings (est.): Feb 23, 2027, after close
Exchange: Nasdaq
Industry: Services-Medical Laboratories
Fiscal year ends: December 31
Employees: 765
Held by institutions: 100.0%
Auditor: Deloitte & Touche LLP
SEC CIK: 1217234

Advertisement
300 × 250

See a number that looks wrong?

CareDx EV/EBITDA

EV/EBITDA at the end of each year

More CareDx figures